Last updated on 15-1-2025 by Joris Van Loenhout
Téléchargement 319.45 KoAuteurs
Mario Fontán-Vela; Kissling, Esther; Nathalie Nicolay; Toon Braeye; Izaak Van Evercooren; Christian Holm Hansen; Hanne-Dorthe Emborg; Massimo Fabiani; Alberto Mateo-Urdiales; Ala'a AlKerwi; Susanne Schmitz; Jesús Castilla; Iván Martínez-Baz; Brechje de Gier; Susan Hahné; Hinta Meijerink; Jostein Starrfelt; Baltazar Nunes; Caetano, Constantino; Tarik Derrough; Anthony Nardone; Susana MongeMots-clés
Article written during project(s) :
Résumé:
To monitor relative vaccine effectiveness (rVE) against COVID-19-related hospitalisation of the first, second and third COVID-19 booster (vs complete primary vaccination), we performed monthly Cox regression models using retrospective cohorts constructed from electronic health registries in eight European countries, October 2021-July 2023. Within 12 weeks of administration, each booster showed high rVE (≥ 70% for second and third boosters). However, as of July 2023, most of the relative benefit has waned, particularly in persons ≥ 80-years-old, while some protection remained in 65-79-year-o…